Previous close | 45.73 |
Open | 45.73 |
Bid | 54.60 x 40000 |
Ask | 59.42 x 40000 |
Day's range | 45.73 - 45.73 |
52-week range | 35.91 - 45.73 |
Volume | |
Avg. volume | 169 |
Market cap | 29.902B |
Beta (5Y monthly) | 0.27 |
PE ratio (TTM) | 24.99 |
EPS (TTM) | 1.58 |
Earnings date | 29 Oct 2024 - 04 Nov 2024 |
Forward dividend & yield | 0.80 (2.02%) |
Ex-dividend date | 27 Dec 2024 |
1y target est | N/A |
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
PALO ALTO, Calif., November 10, 2023--Recor Medical, Inc. announces the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation system for the treatment of hypertension.